The Kawartha Centre has agreed to participate in IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).
Renowned clinical researcher, Dr. Donald Doell, has agreed to serve as the site’s lead investigator.
BUENA is a randomized, double-blind, placebo-controlled Phase 2a proof-of- concept study designed to assess Montelukast VersaFilm in about 70 patients with mild-to-moderate AD. BUENA will evaluate the safety, feasibility, tolerability, and efficacy of montelukast buccal film following daily dosing for 26 weeks.
In a recent Phase 1 study, IntelGenx demonstrated that an oral film formulation of montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability, compared with the regular Montelukast tablet, demonstrating a clear advantage of delivering montelukast via film. IntelGenx’s oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.
Based in Peterborough, Ontario, the Kawartha Centre’s corporate vision is to redefine healthy aging through expert, comprehensive, compassionate care for people facing memory loss, dementia and other related challenges. Its vision is to improve the lives of patients, families, caregivers and communities from assessment and treatment to research and advocacy.
